Survival benefit of empirical therapy for staphylococcus aureus bloodstream infections in infants

Pediatric Infectious Disease Journal

Volumn 34, Issue 11, 2015, Pages 1175-1179

  Thaden, Joshua T ^a   Ericson, Jessica E ^a,b   Cross, Heather ^b   Bergin, Stephen P ^a   Messina, Julia A ^a,b   Fowler, Vance G ^a,b   Benjamin, Daniel K ^a,b   Clark, Reese H ^c   Hornik, Christoph P ^a,b   Smith, P Brian ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Mednax National Medical Group   (United States)

Author keywords

Early empirical antibiotic therapy; Infants; NICU; Staphylococcus aureus bloodstream infection

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; BLOODSTREAM INFECTION; FEMALE; HOSPITAL DISCHARGE; HUMAN; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; SURVIVAL; EMPIRICAL RESEARCH; INFANT; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; EMPIRICAL RESEARCH; HUMANS; INFANT; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 84944200931     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000850     Document Type: Article

References (40)

1. Burke RE, Halpern MS, Baron EJ, et al. Pediatric and neonatal Staphylococcus aureus bacteremia: Epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol. 2009;30:636-644.
2. Carey AJ, Duchon J, Della-Latta P, et al. The epidemiology of methicillinsusceptible and methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit, 2000-2007. J Perinatol. 2010;30:135-139.
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285-291.
4. Carrillo-Marquez MA, Hulten KG, Mason EO, et al. Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect Dis J. 2010;29:410-414.
5. Gray JW. A 7-year study of bloodstream infections in an English children's hospital. Eur J Pediatr. 2004;163:530-535.
6. Hultén KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infect Control Hosp Epidemiol. 2010;31:183-190.
7. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis. 1996;23:255-259.
8. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br J Exp Pathol. 1957;38:573-586.
9. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004;364:703-705.
10. Herzke CA, Chen LF, Anderson DJ, et al. Empirical antimicrobial therapy for bloodstream infection due to methicillin-resistant Staphylococcus aureus: no better than a coin toss. Infect Control Hosp Epidemiol. 2009;30:1057-1061.
11. Kim SH, Park WB, Lee KD, et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2004;54:489-497.
12. Lee CC, Hong MY, Chan TY, et al. The impact of appropriateness of antimicrobial therapy in adults with occult bacteraemia. Emerg Med J. 2014;31:53-58.
13. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418-1423.
14. Metsvaht T, Ilmoja ML, Parm U, et al. Comparison of ampicillin plus gentamicin vs. penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatrica. 2010;99:665-672.
15. Miall-Allen VM, Whitelaw AG, Darrell JH. Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections. Br J Clin Pract. 1988;42:273-279.
16. Snelling S, Hart CA, Cooke RW. Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old. J Antimicrob Chemother. 1983;12 (suppl A):353-356.
17. Spitzer AR, Ellsbury DL, Handler D, et al. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system- Tools for "meaningful use" in continuous quality improvement. Clin Perinatol. 2010;37:49-70.
18. Olsen IE, Groveman SA, Lawson ML, et al. New intrauterine growth curves based on United States data. Pediatrics. 2010;125:e214-e224.
19. Frederiksen MS, Espersen F, Frimodt-Møller N, et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. Pediatr Infect Dis J. 2007;26:398-405.
20. Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: A 5-year retrospective review. J Paediatr Child Health. 2002;38:290-294.
21. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695-701.
22. Shane AL, Hansen NI, Stoll BJ, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics. 2012;129:e914-e922.
23. Marchaim D, Kaye KS, Fowler VG, et al. Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2010;16:747-752.
24. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med. 2006;34:2069-2074.
25. Soriano A, Martínez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000;30:368-373.
26. Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658-2665.
27. Allard C, Carignan A, Bergevin M, et al. Secular changes in incidence and mortality associated with Staphylococcus aureus bacteraemia in Quebec, Canada, 1991-2005. Clin Microbiol Infect. 2008;14:421-428.
28. Ammerlaan H, Seifert H, Harbarth S, et al; European Practices of Infections with Staphylococcus aureus (SEPIA) Study Group. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis. 2009;49:997-1005.
29. Libert M, Elkholti M, Massaut J, et al. Risk factors for methicillin resistance and outcome of Staphylococcus aureus bloodstream infection in a Belgian university hospital. J Hosp Infect 2008;68:17-24.
30. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med. 2000;160:1001-1004.
31. Chan KE, Warren HS, Thadhani RI, et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol. 2012;23:1551-1559.
32. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003;82:333-339.
33. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38:7-14.
34. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192-197.
35. Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.
36. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190-196.
37. Rana D, Abughali N, Kumar D, et al. Staphylococcus aureus, including community- Acquired methicillin-resistant S. aureus, in a level III NICU: 2001 to 2008. Am J Perinatol. 2012;29:401-408.
38. Day CT, Kaplan SL, Mason EO, et al. Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old. Pediatr Infect Dis J 2014;33:98-100.
39. Dantes R, Mu Y, Belflower R, et al; Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173:1970-1978.
40. Kallen AJ, Mu Y, Bulens S, et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Health careassociated invasive MRSA infections, 2005-2008. JAMA. 2010;304:641-648.